{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tetanus+booster", "query": { "intervention": "Tetanus booster" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 36, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tetanus+booster&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-06T09:25:28.381Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05077137", "title": "A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Tetanus Diptheria Vaccine", "type": "BIOLOGICAL" }, { "name": "Polio Boost Immunization", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2021-09-07", "completion_date": "2027-07-01", "has_results": false, "last_update_posted_date": "2026-07-08", "last_synced_at": "2026-09-06T09:25:28.381Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05077137" }, { "nct_id": "NCT02864368", "title": "Peptide Targets for Glioblastoma Against Novel Cytomegalovirus Antigens", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma", "Glioblastoma Multiforme" ], "interventions": [ { "name": "5-day TMZ", "type": "DRUG" }, { "name": "21-day TMZ", "type": "DRUG" }, { "name": "PEP-CMV: Component A", "type": "BIOLOGICAL" }, { "name": "Tetanus-Diphtheria booster", "type": "DRUG" }, { "name": "Tetanus Pre-Conditioning", "type": "DRUG" }, { "name": "PEP-CMV: Component B", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Eric Thompson, M.D.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2016-12-07", "completion_date": "2020-06-15", "has_results": true, "last_update_posted_date": "2022-06-09", "last_synced_at": "2026-09-06T09:25:28.381Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02864368" }, { "nct_id": "NCT00282295", "title": "US-licensed Combined Vaccine Against Tetanus & Diphtheria, Given With US-licensed Vaccine Against Meningococcal Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Acellular Pertussis", "Tetanus", "Diphtheria" ], "interventions": [ { "name": "Boostrix®", "type": "BIOLOGICAL" }, { "name": "Menactra™", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "11 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "11 Years to 18 Years" }, "enrollment_count": 1344, "start_date": "2006-01-25", "completion_date": "2006-08-08", "has_results": true, "last_update_posted_date": "2018-08-17", "last_synced_at": "2026-09-06T09:25:28.381Z", "location_count": 24, "location_summary": "Chandler, Arizona • Little Rock, Arkansas • Fountain Valley, California + 18 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Golden", "state": "Colorado" }, { "city": "Marietta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00282295" }, { "nct_id": "NCT00289783", "title": "Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Haemophilus Influenzae Type b", "Neisseria Meningitidis" ], "interventions": [ { "name": "GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis 792014 vaccine", "type": "BIOLOGICAL" }, { "name": "ActHIB", "type": "BIOLOGICAL" }, { "name": "PedvaxHIB", "type": "BIOLOGICAL" }, { "name": "Pediarix", "type": "BIOLOGICAL" }, { "name": "Prevnar", "type": "BIOLOGICAL" }, { "name": "M-M-R II", "type": "BIOLOGICAL" }, { "name": "Varivax", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "6 Weeks", "maximum_age": "15 Months", "sex": "ALL", "summary": "6 Weeks to 15 Months" }, "enrollment_count": 4441, "start_date": "2006-02-22", "completion_date": "2008-02-26", "has_results": true, "last_update_posted_date": "2018-08-24", "last_synced_at": "2026-09-06T09:25:28.381Z", "location_count": 88, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Bryant, Arkansas + 76 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Bryant", "state": "Arkansas" }, { "city": "Fayetteville", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00289783" }, { "nct_id": "NCT00369291", "title": "CpG 7909 in Treating Patients Who Have Undergone Autologous Stem Cell Transplant", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Germ Cell Tumor", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm" ], "interventions": [ { "name": "keyhole limpet hemocyanin", "type": "BIOLOGICAL" }, { "name": "tetanus toxoid", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2003-09", "completion_date": "2010-05", "has_results": false, "last_update_posted_date": "2017-11-29", "last_synced_at": "2026-09-06T09:25:28.381Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00369291" }, { "nct_id": "NCT02096263", "title": "Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Poliomyelitis", "Diphtheria", "Haemophilus Influenzae Type b", "Tetanus", "Acellular Pertussis", "Hepatitis B" ], "interventions": [ { "name": "Infanrix hexa", "type": "BIOLOGICAL" }, { "name": "Pediarix", "type": "BIOLOGICAL" }, { "name": "ActHIB", "type": "BIOLOGICAL" }, { "name": "Pentacel", "type": "BIOLOGICAL" }, { "name": "Engerix-B", "type": "BIOLOGICAL" }, { "name": "Infanrix", "type": "BIOLOGICAL" }, { "name": "Hiberix", "type": "BIOLOGICAL" }, { "name": "Prevnar13", "type": "BIOLOGICAL" }, { "name": "Rotarix", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "6 Weeks", "maximum_age": "12 Weeks", "sex": "ALL", "summary": "6 Weeks to 12 Weeks" }, "enrollment_count": 585, "start_date": "2014-04-16", "completion_date": "2015-11-13", "has_results": true, "last_update_posted_date": "2019-11-27", "last_synced_at": "2026-09-06T09:25:28.381Z", "location_count": 43, "location_summary": "Tucson, Arizona • Fayetteville, Arkansas • Anaheim, California + 38 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Daly City", "state": "California" }, { "city": "Fresno", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02096263" }, { "nct_id": "NCT03334305", "title": "Adoptive Cellular Therapy in Pediatric Patients With High-grade Gliomas", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Malignant Glioma", "High Grade Glioma" ], "interventions": [ { "name": "TTRNA-DC vaccines with GM-CSF", "type": "BIOLOGICAL" }, { "name": "Dose-intensified TMZ", "type": "DRUG" }, { "name": "Autologous Hematopoietic Stem cells (HSCs)", "type": "BIOLOGICAL" }, { "name": "TTRNA-xALT", "type": "BIOLOGICAL" }, { "name": "Td vaccine", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "University of Florida", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "3 Years to 21 Years" }, "enrollment_count": 18, "start_date": "2018-08-27", "completion_date": "2025-03-20", "has_results": true, "last_update_posted_date": "2026-04-23", "last_synced_at": "2026-09-06T09:25:28.381Z", "location_count": 3, "location_summary": "Birmingham, Alabama • Washington D.C., District of Columbia • Gainesville, Florida", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03334305" }, { "nct_id": "NCT03848182", "title": "Analyzing Childhood Recall Antigens in Patients With Pancreatic Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "Gemcitabine", "type": "DRUG" }, { "name": "TT vaccine booster", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Albert Einstein College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 10, "start_date": "2017-07-21", "completion_date": "2019-11-11", "has_results": true, "last_update_posted_date": "2024-04-18", "last_synced_at": "2026-09-06T09:25:28.381Z", "location_count": 1, "location_summary": "The Bronx, New York", "locations": [ { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03848182" }, { "nct_id": "NCT00345579", "title": "Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 2, 4, 6 and 12 to 15 Months of Age", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Haemophilus Influenzae Type b", "Neisseria Meningitidis" ], "interventions": [ { "name": "GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined 792014", "type": "BIOLOGICAL" }, { "name": "ActHIB", "type": "BIOLOGICAL" }, { "name": "Pediarix/Infanrix Penta", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "6 Weeks", "maximum_age": "12 Weeks", "sex": "ALL", "summary": "6 Weeks to 12 Weeks" }, "enrollment_count": 4432, "start_date": "2006-09", "completion_date": "2008-03", "has_results": true, "last_update_posted_date": "2016-12-16", "last_synced_at": "2026-09-06T09:25:28.381Z", "location_count": 61, "location_summary": "Birmingham, Alabama • Benton, Arkansas • Fayetteville, Arkansas + 51 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Benton", "state": "Arkansas" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Hot Springs", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00345579" }, { "nct_id": "NCT06254326", "title": "ADAGiO: Adoptive Cellular Therapy for the TreAtment of Recurrent OliGodendrogliOma (OG) Adult Patients", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Oligodendroglioma", "Progressive Oligodendroglioma" ], "interventions": [ { "name": "TTRNA-DC vaccines with GM-CSF", "type": "BIOLOGICAL" }, { "name": "Autologous Hematopoietic Stem cells (HSCs)", "type": "BIOLOGICAL" }, { "name": "TTRNA-xALT", "type": "BIOLOGICAL" }, { "name": "Td vaccine", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "University of Florida", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "89 Years", "sex": "ALL", "summary": "18 Years to 89 Years" }, "enrollment_count": 12, "start_date": "2024-09-19", "completion_date": "2028-06", "has_results": false, "last_update_posted_date": "2026-05-27", "last_synced_at": "2026-09-06T09:25:28.381Z", "location_count": 1, "location_summary": "Gainesville, Florida", "locations": [ { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06254326" } ] }